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Objective: to review the current role and results of angioplasty in the management of critical limb ischaemia (CLI) in a
single institution.
Methods: data on 526 patients with 608 ischaemic limbs, treated between January 1994 and December 1999 was collected
prospectively and analysed retrospectively. Patients were divided into 3 groups according to the date of presentation:
group 1 (1994±95), group 2 (1996±97) and group 3 (1998±99). The groups were comparable in terms of demographics,
mode of presentation and level of disease.
Results: Revascularisation was attempted in 87%, 81% and 91% for groups 1, 2 and 3 respectively (NS). Primary
percutaneous transluminal angioplasty (PTA) rates increased from 44% (1994±95) to 69% (1998±99) (p5 0.001), and
surgical revascularisation rates decreased correspondingly (p5 0.01). Overall cumulative patient survival and limb
salvage rates were 82% and 89% for 1 year and 45% and 87% for 5 years, respectively. No statistically significant
difference existed between the three groups regarding patient survival, limb salvage rates and mean hospital stay (19, 12
and 12 days, respectively).
Conclusion: PTA is increasingly replacing bypass surgery in the treatment of CLI, without compromising patient survival
or limb salvage rates.
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The Audit Committee of the Vascular Surgical Society
of Great Britain and Ireland defined Critical limb
ischaemia (CLI) as chronic or acute on chronic ischae-
mia that endangers the whole or part of a leg.1 CLI is a
common problem. Its incidence is estimated to be
between 50±100 cases per 100 000 population per
year.2 The second European consensus document on
CLI estimated that only 66% of critically ischaemic
limbs undergo revascularisation versus 16% which
undergo primary major amputation, 10% which
require medical or minor surgical treatment, and 8%
which receive symptomatic relief only.2 The refine-
ment of bypass surgery and endovascular procedures
has led many to argue that revascularisation should be
attempted in more patients.3
CLI was previously considered as a primary indica-
tion for bypass surgery, and percutaneous translum-
inal angioplasty (PTA) only considered if the patient* Please address correspondence to: M. Horrocks, Royal United
Hospital, Combe Park, Bath BA1 3NG, U.K.
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material was not available.4,5 In 1991, only about 20%
of limbs with critical ischaemia were considered suit-
able for PTA.6 Recent studies have shown a trend
towards more utilisation of PTA as a first line treat-
ment for CLI from 23% to 46%.7±11 This study reviews
the role of PTA in the management of CLI in our
institution over a 6-year period, and assess the results
of an aggressive policy towards revascularisation,
where PTA was used as a first line treatment, and
surgical bypass was reserved for those where angio-
plasty was either inappropriate or unsuccessful.
Patients and Methods
Patients
A total of 526 patients with 608 chronic critically
ischaemic limbs admitted to the vascular unit at the
Royal United Hospital Bath between January 1994 and
December 1999 are included. CLI was defined by
the clinical definition of the Audit Committee of thecience Ltd
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(the presence of rest pain for at least two weeks
or tissue necrosis). Patients were grouped into three
groups according to the date of presentation. Group 1
(185 patients with 222 ischaemic limbs) presented
during 1994 and 1995. Group 2 (180 patients with
204 ischaemic limbs) presented during 1996 and 1997
and group 3 (161 patients with 182 ischaemic limbs)
presented during 1998 and 1999.
Management
An active revascularisation policy was used except in
cases where it was deemed that the limb was clinically
unsalvageable or the patient unfit for revascularisa-
tion (e.g. wheelchair bound or severely demented
patients). Patients considered for revascularisation
were assessed with colour Duplex scanning and then
angiography with a view to proceed to PTA if possible.
Bypass surgery was reserved for patients either unsuit-
able for PTA, according to the surgeon and radiologist
judgement, or in whom PTA had failed (according to
angiographic morphology, post-procedure ABPI, or
persistence of symptoms). All patients were then
started on antiplatelet therapy (low dose aspirin or
clopidogrel where aspirin was contraindicated).
Follow-up
All patients who had a surgical bypass were followed-
up in a clinical and duplex graft surveillance pro-
gramme and reviewed at 6 weeks, 3 months, 6 months,
12 months and then annually. PTA patients were
followed-up clinically at the vascular clinic until
their rest pain, ulcers or gangrene had healed, then
they were discharged from follow-up, unless their
symptoms recurred in which case they were seen
urgently in a one-stop vascular and duplex clinic
(patients were encouraged to contact the vascular
department directly on recurrence of symptoms).Table 1. Patients demographics and mode of presentation.
Group 1 Group 2
Patients 185 180
Median age (years) 75 (67±81) 78 (70±84)
Females 87 (47) 91 (50)
Diabetics 45 (24) 43 (24)
Limbs 222 204
Necrosis 129 (58) 116 (57)
Rest Pain 93 (42) 88 (43)
Values between parentheses are percentages, except for median age (iData collection and analysis
Patients details were entered into a computerised
database which was updated regularly with the
details of outpatient visits, hospital admissions and
mortality. General practitioners were contacted or
the patients were contacted directly if they did not
re-attend or were discharged from follow-up to deter-
mine eventual outcome; all patients were accounted
for. The study endpoints were mortality and/or major
amputations.
Statistics
Statistical analysis was performed through a compu-
terised software package `StatsDirect, CamCode,
U.K.'. Cumulative patient survival and limb salvage
rates were calculated by the Kaplan±Meier method
with Cox regression. Discrete variables were analysed
with the Chi-squared test. Continuous variables are
expressed as medians (interquartile range). Statistical
significance was taken at p values 0.05.
Results
Patients
Patients demographics and mode of presentation are
presented in Table 1. There was no statistical differ-
ence between the groups in terms of age, gender, or
mode of presentation. Distribution of the site of the
disease was not statistically different between the
three groups.
Management
Table 2 shows the primary management for the all
groups. Revascularisation was attempted in 87%,
81% and 91% for groups 1, 2 and 3 respectively (NS).
Primary major amputation rates were not statisticallyGroup 3 Total p value
161 526 ±
76 (69±82) 77 (70±84) NS
86 (53) 264 (50) NS
52 (32) 140 (27) NS
182 608 ±
111 (61) 356 (59) NS
71 (49) 252 (41) NS
nterquartile range). NSnot significant.
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respectively. The percentage of limbs treated by PTA
as the sole treatment increased from 44% for group 1,
to 56% for group 2, and 69% for group 3 (p5 0.001).
Bypass surgery rates decreased from 36% to 21% and
18% respectively (p 0.003).
Table 3 shows the changing role of PTA in the man-
agement of CLI according to the site of the disease at
presentation. These data demonstrate that the role
of PTA has significantly increased in the treatment of
aortoiliac (p5 0.0001) and femoropopliteal disease
(p 0.002). Although our data showed an increase of
PTA in the treatment of crural disease it was not
statistically significant (p 0.2). The rate of repeat
(same site) or additional (different site) PTA (due to
restenosis, reocclusion, or new lesion as detected by
re-investigation after recurrence of symptoms),
decreased from 39% for group 1 to 21% for group 2
and 12% for group 3 (p 0.0005).
Patient survival and limb salvage
Actuarial 30-day mortality rates were 1.5% for PTA
and 5% for bypass surgery (NS) for all patients. There
was no difference in 30-day mortality between the 3
groups. Cumulative patient survival and limb salvage
rates for all patients were 82% and 89% for 1 year, 63%Table 2. Primary management.
Group 1 Group 2 Group 3
Limbs 222 204 182
Revascularisation: 193 (87) 165 (81) 166 (91)
PTA 97 (44) 116 (56) 125 (69)
Surgery 80 (36) 43 (21) 33 (18)
Combined 16 (7) 6 (4) 8 (4)
Major amputation 16 (7) 20 (10) 11 (6)
Conservative 13 (6) 19 (9) 5 (3)
Values between parenthesis are percentages of the total number of
limbs. PTA: percutaneous transluminal angioplasty, Combined: PTA
and surgery for multiple iesions, Major amputation: above or below
knee amputation, Conservative: symptomatic treatment or minor
amputation (toes or forefoot amputation).
Table 3. Revascularisation procedures, according to the site of disea
Group 1 (193 limbs) Group
PTA Surg. Comb. PTA
Aortoiliac 10 (29) 22 (63) 3 (8) 26 (66)
Femoro-popliteal 81 (59) 47 (34) 10 (7) 75 (77)
Crural 6 (31) 11 (54) 3 (15) 15 (55)
Total 97 (50) 80 (42) 16 (8) 116 (70
Values between parenthesis are percentages. PTA: percutaneous translu
bypass surgery.
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respectively. Cumulative patient survival and limb
salvage rates were not statistically different between
the three groups at mid-term follow up (up to 2 years,
Figures 1 and 2 respectively).
Mean hospital stay was not statistically different
between the three groups (19, 12 and 12 days respec-
tively). Diabetes did not influence patient survival in
this series. Limb salvage rate was not influenced by
the presence/absence of diabetes, site of the disease or
mode of presentation.
Discussion
The findings of a large prospective cohort study of
1560 patients confirm the poor prognosis of CLI. The
overall mortality rate at 12 months (19.1%) indicates
that the prognosis is similar to that of myocardial
infarction and stroke. The suitability and practicability
of revascularisation profoundly affected the prognosis
of the patients. Compared with patients for whom
revascularisation was deemed unnecessary, the risk
of dying within six or 12 months was double among
patients considered unsuitable for intervention.12
The management of CLI is a major part of the
workload in any vascular unit. With continuing
improvements in endovascular technology and ex-
pertise, an increasing proportion of patients with CLI
can he treated by PTA. Successful angioplasty or sur-
gical intervention lead to a similar degree of quality of
life improvement in CLL.13 A deliberate policy in this
unit to use PTA as a first-line treatment whenever
possible has resulted in a significant increase in the
proportion of patients treated by angioplasty com-
pared to other studies (see Fig. 3).
Patient survival and limb salvage
Our one-year cumulative patient survival and limb
salvage rates of 82 and 89% respectively, comparese.
2 (165 limbs) Group 3 (166 limbs)
Surg. Comb. PTA Surg. Comb.
13 (33) 1 (1) 36 (77) 7 (16) 3 (7)
18 (18) 5 (5) 76 (79) 18 (19) 2 (2)
12 (45) 0 (0) 13 (54) 8 (33) 3 (13)
) 43 (26) 6 (4) 125 (75) 33 (20) 8 (5)
minal angioplasty, Surg.: bypass surgery, Comb.: combined PTA and
Fig. 1. Cumulative patient survival rates according to groups.
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tages of primary PTA were much lower, ranging from
20% to 46%. Beside the higher rate of primary PTA in
our series, the rate of revascularisation (averaging 86%
during the 6-year period) is much higher than other
series and of that of the second European consensus
document on CLI.2,6±11 This high rate of revascularisa-
tion was probably the reason for the good limb sal-
vage rate.
Hospital stay, cost implications and
resources allocation
Despite earlier reports of shorter hospital stay for
PTA, we have found no significant difference in
mean hospital stay (which is the major contribu-
tor to the cost of management) between the three
groups.11,14,15This was probably due to the similar
degree of ischaemia and tissue loss suffered by the
patients whose duration of inpatient stay and rehabili-
tation needs were comparable.Our results show an increase in PTA utilisation,
especially for aortoiliac and femoropopliteal disease,
77% and 79% respectively and even for crural disease
(55%), this is in line with other studies which showed
that infrapopliteal PTA is a feasible primary treatment
for CLI with angiographic and clinical success and a
cumulative limb salvage rate comparable to that of
surgical revascularisation.16
The increase in PTA utilisation and the correspond-
ing decrease in surgical revascularisation should call
for a change in vascular surgical and radiological
resources allocation. It also raises the question of the
need for a review of vascular training with more
emphasis on endovascular training for vascular
surgery trainees.
Conclusions
Although we did not demonstrate any statistically
significant difference in favour of either treatment,Eur J Vasc Endovasc Surg Vol 23, May 2002
Fig. 2. Cumulative limb salvage rates according to groups.
Fig. 3. PTA as a sole intervention for CLI.
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for the high-risk, elderly vascularly compromised
patient.8 The present study suggests that PTA should
increasingly replace revascularisation surgery in the
primary management of CLI, emphasising that team-
work between vascular surgeons and radiologists is
essential for good vascular practice. The increase in
revascularisation for CLI should be supported by
adequate funding for surgical and radiological services.
Finally the high rate of mortality reflects co-existent
morbidity and calls for an integrated approach to treat-
ment of the patient's other medical conditions.
Acknowledgements
We wish to express our gratitude to Mr. J. Budd for allowing us to
include patients under his care into the study.
References
1 Recommendations for the management of chronic critical lower
limb ischaemia. The Audit Committee of the Vascular Surgical
Society of Great Britain and Ireland. Eur J Vasc Endovasc Surg
1996; 12: 131±135.
2 Second European Consensus Document on Chronic Critical Leg
Ischaemia. Eur J Vasc Surg 1992; 6: 1±32.
3 Perler BA. Cost-efficacy issues in the treatment of peripheral
vascular disease: primary amputation or revascularization
for limb-threatening ischemia. J Vasc Interv Radiol 1995; 6: 111S±
115S.
4 Steinberg EP, Bass EB, Tunis SR. Interventional management of
peripheral vascular disease: what did we learn in Maryland and
where do we go from here? [comment]. Radiology 1993; 186: 639±
642.5 Johnston KW. Femoral and popliteal arteries: reanalysis of
results of balloon angioplasty [see comments]. Radiology 1992;
183: 767±771.
6 Cooper JC, Welsh CL. The role of percutaneous transluminal
angioplasty in the treatment of critical ischaemia. Eur J Vasc Surg
1991; 5: 261±264.
7 Sayers RD, Thompson MM, Hartshorne T, Budd JS, Bell PR.
Treatment and outcome of severe lower-limb ischaemia. Br J Surg
1994; 81: 521±523.
8 London NJ, Varty K, Sayers RD, Thompson MM, Bell PR,
Bolia A. Percutaneous transluminal angioplasty for lower-limb
critical ischaemia [see comments]. Br J Surg 1995; 82: 1232±235.
9 Varty K, Nydahl S, Butterworth P et al. Changes in the
management of critical limb ischaemia. Br J Surg 1996; 83: 953±
956.
10 Varty K, Nydahl S, Nasim A et al. Results of surgery and
angioplasty for the treatment of chronic severe lower limb
ischaemia. Eur J Vasc Endovasc Surg 1998; 16: 159±163.
11 Singh S, Evans L, Datta D, Gaines P, Beard JD. The costs of
managing lower limb-threatening ischaemia. Eur J Vasc Endovasc
Surg 1996; 12: 359±362.
12 Bertele V, Roncaglioni MC, Pangrazzi J, Terzian E, Tognoni
EG. Clinical outcome and its predictors in 1560 patients with
critical leg ischaemia. Chronic Critical Leg Ischaemia Group. Eur
J Vasc Endovasc Surg 1999; 18: 401±410.
13 Klevsgard R, Hallberg IR, Risberg B, Thomsen MB. The
effects of successful intervention on quality of life in patients
with varying degrees of lower-limb ischaemia. Eur J Vasc Endo-
vasc Surg 2000; 19: 238±245.
14 Mackey WC, Mccullough JL, Conlon TP et al. The costs of
surgery for limb-threatening ischemia. Surgery 1986; 99: 26±35.
15 Gupta SK, Veith FJ, Ascer E, Flores SA, Gliedman ML.
Cost factors in limb-threatening ischaemia due to infrainguinal
arteriosclerosis. Eur J Vasc Surg 1988; 2: 151±154.
16 Soder HK, Manninen HI, Jaakkola P et al. Prospective trial of
infrapopliteal artery balloon angioplasty for critical limb ische-
mia: angiographic and clinical results. J Vasc Interv Radiol 2000;
11: 1021±1031.
Accepted 31 January 2002Eur J Vasc Endovasc Surg Vol 23, May 2002
